Related Experiment Video
Updated: May 25, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Bioequivalence challenges in development of fixed-dose combination products: looking beyond reformulation
1Dr. Reddy's Laboratories Ltd., Integrated Product Development, Innovation Plaza, Bachupalli, Hyderabad, India. dubeyr@drreddys.com
Expert Opinion on Drug Delivery
|January 19, 2012
Summary
Achieving bioequivalence for fixed-dose combination products (FDCPs) is crucial. Evaluating pharmacokinetic interactions and clinical significance can prevent costly reformulation delays.
Area of Science:
- Pharmaceutical development
- Pharmacokinetics
- Drug formulation
Background:
- Bioequivalence studies are essential for developing fixed-dose combination products (FDCPs).
- Failure to achieve bioequivalence can cause significant development delays and necessitate reformulation.
Purpose of the Study:
- To highlight pharmacokinetic (PK) challenges in FDCP development.
- To present strategies for resolving PK challenges and mitigating development risks.
Main Methods:
- Review of pharmacokinetic interactions in FDCPs.
- Analysis of strategies for addressing bioequivalence issues.
Main Results:
- Pharmacokinetic interactions can impede FDCP development.
- A rationale approach can minimize development timelines.
Conclusions:
- Integrating formulation and clinical insight is key to understanding non-bioequivalence.
- Evaluating PK and clinical implications of actives in approved FDCPs aids pragmatic decision-making.
- This approach facilitates clinical studies, enhancing productivity without compromising safety or efficacy.
Related Concept Videos
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...